Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Hellstrand

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II studyF Donskov, H von der Maase, R Henriksson, et al.
Journal of Viral Hepatitis|June 23, 2011
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1M Lindh, M Lagging, B Arnholm, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 25, 2011
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infectionA Alsiö, A Jannesson, N Langeland, et al.
Journal of Viral Hepatitis|March 16, 2013
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirinM Lindh, B Arnholm, P Björkman, et al.
Journal of Hepatology|March 1, 2011
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis CP-Y Bochud, S Bibert, F Negro, et al.
Leukemia|May 23, 2017
Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemiaE Bernson, A Hallner, F E Sander, et al.
Journal of Viral Hepatitis|May 27, 2010
Hepatitis C treatment response kinetics and impact of baseline predictorsM Lindh, B Arnholm, A Eilard, et al.
Journal of Viral Hepatitis|September 13, 2002
A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis CY Lurie, F Nevens, Z G Aprosina, et al.
Journal of Viral Hepatitis|January 11, 2007
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infectionJ Westin, M Lagging, A P Dhillon, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2002
Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II studyF Donskov, H von der Maase, R Henriksson, et al.
Journal of Viral Hepatitis|June 23, 2011
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1M Lindh, M Lagging, B Arnholm, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 25, 2011
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infectionA Alsiö, A Jannesson, N Langeland, et al.
Journal of Viral Hepatitis|March 16, 2013
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirinM Lindh, B Arnholm, P Björkman, et al.
Journal of Hepatology|March 1, 2011
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis CP-Y Bochud, S Bibert, F Negro, et al.
Leukemia|May 23, 2017
Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemiaE Bernson, A Hallner, F E Sander, et al.
Journal of Viral Hepatitis|May 27, 2010
Hepatitis C treatment response kinetics and impact of baseline predictorsM Lindh, B Arnholm, A Eilard, et al.
Journal of Viral Hepatitis|September 13, 2002
A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis CY Lurie, F Nevens, Z G Aprosina, et al.
Journal of Viral Hepatitis|January 11, 2007
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infectionJ Westin, M Lagging, A P Dhillon, et al.
Pageof 7